Peter A. Thompson Sells 10,300 Shares of Adaptimmune Therapeutics (ADAP) Stock

Adaptimmune Therapeutics (NASDAQ:ADAP) Director Peter A. Thompson sold 10,300 shares of the business’s stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $13.50, for a total transaction of $139,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ ADAP opened at $12.02 on Friday. The company has a market cap of $1.16 billion, a P/E ratio of -15.03 and a beta of 1.17. Adaptimmune Therapeutics has a 52 week low of $12.39 and a 52 week high of $12.95.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The firm had revenue of $4.27 million for the quarter, compared to the consensus estimate of $9.38 million. Adaptimmune Therapeutics had a negative return on equity of 32.57% and a negative net margin of 160.83%. analysts forecast that Adaptimmune Therapeutics will post -0.87 earnings per share for the current year.

Several equities research analysts have recently commented on the stock. BidaskClub lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. SunTrust Banks boosted their price target on shares of Adaptimmune Therapeutics to $18.00 and gave the company a “buy” rating in a report on Thursday, May 10th. Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a report on Wednesday, May 9th. Raymond James set a $20.00 price objective on shares of Adaptimmune Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 9th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $15.69.

Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. NEA Management Company LLC raised its stake in shares of Adaptimmune Therapeutics by 10.9% during the 1st quarter. NEA Management Company LLC now owns 13,332,611 shares of the biotechnology company’s stock worth $149,725,000 after acquiring an additional 1,306,612 shares in the last quarter. BlackRock Inc. raised its stake in shares of Adaptimmune Therapeutics by 43,632.6% during the 4th quarter. BlackRock Inc. now owns 787,187 shares of the biotechnology company’s stock worth $5,258,000 after acquiring an additional 785,387 shares in the last quarter. Millennium Management LLC raised its stake in shares of Adaptimmune Therapeutics by 83.4% during the 1st quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock worth $16,594,000 after acquiring an additional 672,046 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics by 33.6% during the 1st quarter. Baillie Gifford & Co. now owns 2,565,409 shares of the biotechnology company’s stock worth $28,810,000 after acquiring an additional 644,816 shares in the last quarter. Finally, Foresite Capital Management II LLC bought a new position in shares of Adaptimmune Therapeutics during the 1st quarter worth approximately $4,492,000. Hedge funds and other institutional investors own 55.78% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply